Journal of Inherited Metabolic Disease

, Volume 31, Issue 1, pp 108–116 | Cite as

Analysis of UDP-galactose 4′-epimerase mutations associated with the intermediate form of type III galactosaemia

  • J. S. Chhay
  • C. A. Vargas
  • T. J. McCorvie
  • J. L. Fridovich-Keil
  • D. J. Timson
Original Article

Summary

Type III galactosaemia is a hereditary disease caused by reduced activity in the Leloir pathway enzyme, UDP-galactose 4′-epimerase (GALE). Traditionally, the condition has been divided into two forms—a mild, or peripheral, form and a severe, or generalized, form. Recently it has become apparent that there are disease states which are intermediate between these two extremes. Three mutations associated with this intermediate form (S81R, T150M and P293L) were analysed for their kinetic and structural properties in vitro and their effects on galactose-sensitivity of Saccharomyces cerevisiae cells that were deleted for the yeast GALE homologue Gal10p. All three mutations result in impairment of the kinetic parameters (principally the turnover number, kcat) compared with the wild-type enzyme. However, the degree of impairment was mild compared with that seen with the mutation (V94M) associated with the generalized form of epimerase deficiency galactosaemia. None of the three mutations tested affected the ability of the protein to dimerize in solution or its susceptibility to limited proteolysis in vitro. Finally, in the yeast model, each of the mutated patient alleles was able to complement the galactose-sensitivity of gal10Δ cells as fully as was the wild-type human allele. Furthermore, there was no difference from control in metabolite profile following galactose exposure for any of these strains. Thus we conclude that the subtle biochemical and metabolic abnormalities detected in patients expressing these GALE alleles likely reflect, at least in part, the reduced enzymatic activity of the encoded GALE proteins.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Axelrod J, Kalckar HM, Maxwell ES, Strominger JL (1957) Enzymatic formation of uridine diphosphoglucuronic acid. J Biol Chem 224: 79–90.PubMedGoogle Scholar
  2. Bauer AJ, Rayment I, Frey PA, Holden HM (1991) The isolation, purification, and preliminary crystallographic characterization of UDP-galactose-4-epimerase from Escherichia coli. Proteins 9: 135–142.PubMedCrossRefGoogle Scholar
  3. Bauer AJ, Rayment I, Frey PA, Holden HM (1992) The molecular structure of UDP-galactose 4-epimerase from Escherichia coli determined at 2.5 Å resolution. Proteins 12: 372–381.PubMedCrossRefGoogle Scholar
  4. Berger E, Arabshahi A, Wei Y, Schilling JF, Frey PA (2001) Acid–base catalysis by UDP-galactose 4-epimerase: correlations of kinetically measured acid dissociation constants with thermodynamic values for tyrosine 149. Biochemistry 40: 6699–6705.PubMedCrossRefGoogle Scholar
  5. Bosch AM, Bakker HD, van Gennip AH, van Kempen JV, Wanders RJ, Wijburg FA (2002) Clinical features of galactokinase deficiency: a review of the literature. J Inherit Metab Dis 25: 629–634.PubMedCrossRefGoogle Scholar
  6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.PubMedCrossRefGoogle Scholar
  7. Gitzelmann R (1972) Deficiency of uridine diphosphate galactose 4-epimerase in blood cells of an apparently healthy infant. Helv Paediatr Acta 27: 125–130.PubMedGoogle Scholar
  8. Henderson MJ, Holton JB, MacFaul R (1983) Further observations in a case of uridine diphosphate galactose-4-epimerase deficiency with a severe clinical presentation. J Inherit Metab Dis 6: 17–20.PubMedCrossRefGoogle Scholar
  9. Holden HM, Rayment I, Thoden JB (2003) Structure and function of enzymes of the Leloir pathway for galactose metabolism. J Biol Chem 278: 43885–43888.PubMedCrossRefGoogle Scholar
  10. Holden HM, Thoden JB, Timson DJ, Reece RJ (2004) Galactokinase: structure, function and role in type II galactosemia. Cell Mol Life Sci 61: 2471–2484.PubMedCrossRefGoogle Scholar
  11. Holton JB, Gillett MG, MacFaul R, Young R (1981) Galactosaemia: a new severe variant due to uridine diphosphate galactose-4-epimerase deficiency. Arch Dis Child 56: 885–887.PubMedCrossRefGoogle Scholar
  12. Kallberg Y, Oppermann U, Jornvall H, Persson B (2002a) Short-chain dehydrogenases/reductases (SDRs). Eur J Biochem 269: 4409–4417.CrossRefGoogle Scholar
  13. Kallberg Y, Oppermann U, Jornvall H, Persson B (2002b) Short-chain dehydrogenase/reductase (SDR) relationships: a large family with eight clusters common to human, animal, and plant genomes. Protein Sci 11: 636–641.CrossRefGoogle Scholar
  14. Leslie ND (2003) Insights into the pathogenesis of galactosemia. Annu Rev Nutr 23: 59–80.PubMedCrossRefGoogle Scholar
  15. Maceratesi P, Daude N, Dallapiccola B, et al (1998) Human UDP-galactose 4′ epimerase (GALE) gene and identification of five missense mutations in patients with epimerase-deficiency galactosemia. Mol Genet Metab 63: 26–30.PubMedCrossRefGoogle Scholar
  16. Maitra US, Ankel H (1971) Uridine diphosphate-4-keto-glucose, an intermediate in the uridine diphosphate-galactose-4-epimerase reaction. Proc Natl Acad Sci U S A 68: 2660–2663.PubMedCrossRefGoogle Scholar
  17. Marquardt D (1963) An algorithm for least squares estimation of nonlinear parameters. SIAM J Appl Math 11: 431–441.CrossRefGoogle Scholar
  18. Ng WG, Donnell GN, Hodgman JE, Bergren WR (1967) Differences in uridine diphosphate galactose-4-epimerase between haemolysates of newborns and of adults. Nature 214: 283–284.PubMedCrossRefGoogle Scholar
  19. Openo KK, Schulz JM, Vargas CA et al. (2006) Epimerase-deficiency galactosemia is not a binary condition. Am J Hum Genet 78: 89–102.PubMedCrossRefGoogle Scholar
  20. Quimby BB, Alano A, Almashanu S, DeSandro AM, Cowan TM, Fridovich-Keil JL (1997) Characterization of two mutations associated with epimerase-deficiency galactosemia, by use of a yeast expression system for human UDP-galactose-4-epimerase. Am J Hum Genet 61: 590–598.PubMedCrossRefGoogle Scholar
  21. Ross KL, Davis CN, Fridovich-Keil JL (2004) Differential roles of the Leloir pathway enzymes and metabolites in defining galactose sensitivity in yeast. Mol Genet Metab 83: 103–116.PubMedCrossRefGoogle Scholar
  22. Shaw MP, Bond CS, Roper JR, Gourley DG, Ferguson MA, Hunter WN (2003) High-resolution crystal structure of Trypanosoma brucei UDP-galactose 4′-epimerase: a potential target for structure-based development of novel trypanocides. Mol Biochem Parasitol 126: 173–180.PubMedCrossRefGoogle Scholar
  23. Thoden JB, Holden HM (2005) The molecular architecture of galactose mutarotase/UDP-galactose 4-epimerase from Saccharomyces cerevisiae. J Biol Chem 280: 21900–21907.PubMedCrossRefGoogle Scholar
  24. Thoden JB, Frey PA, Holden HM (1996a) High-resolution X-ray structure of UDP-galactose 4-epimerase complexed with UDP-phenol. Protein Sci 5: 2149–2161.Google Scholar
  25. Thoden JB, Frey PA, Holden HM (1996b) Crystal structures of the oxidized and reduced forms of UDP-galactose 4-epimerase isolated from Escherichia coli. Biochemistry 35: 2557–2566.CrossRefGoogle Scholar
  26. Thoden JB, Hegeman AD, Wesenberg G, Chapeau MC, Frey PA, Holden HM (1997) Structural analysis of UDP-sugar binding to UDP-galactose 4-epimerase from Escherichia coli. Biochemistry 36: 6294–6304.PubMedCrossRefGoogle Scholar
  27. Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM (2000) Crystallographic evidence for Tyr 157 functioning as the active site base in human UDP-galactose 4-epimerase. Biochemistry 39: 5691–5701.PubMedCrossRefGoogle Scholar
  28. Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM (2001) Human UDP-galactose 4-epimerase. Accommodation of UDP-N-acetylglucosamine within the active site. J Biol Chem 276: 15131–15136.PubMedCrossRefGoogle Scholar
  29. Timson DJ (2005) Functional analysis of disease-causing mutations in human UDP-galactose 4-epimerase. FEBS J 272: 6170–6177.PubMedCrossRefGoogle Scholar
  30. Timson DJ (2006) The structural and molecular biology of type III galactosemia. IUBMB Life 58: 83–89.PubMedGoogle Scholar
  31. Walter JH, Roberts RE, Besley GT, et al (1999) Generalised uridine diphosphate galactose-4-epimerase deficiency. Arch Dis Child 80: 374–376.PubMedGoogle Scholar
  32. Wang W, Malcolm BA (1999) Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange Site-Directed Mutagenesis. BioTechniques 26: 680–682.PubMedGoogle Scholar
  33. Wasilenko J, Lucas ME, Thoden JB, Holden HM, Fridovich-Keil JL (2005) Functional characterization of the K257R and G319E-hGALE alleles found in patients with ostensibly peripheral epimerase deficiency galactosemia. Mol Genet Metab 84: 32–38.PubMedCrossRefGoogle Scholar
  34. Wohlers TM, Fridovich-Keil JL (2000) Studies of the V94M-substituted human UDPgalactose-4-epimerase enzyme associated with generalized epimerase-deficiency galactosaemia. J Inherit Metab Dis 23: 713–729.PubMedCrossRefGoogle Scholar
  35. Wohlers TM, Christacos NC, Harreman MT, Fridovich-Keil JL (1999) Identification and characterization of a mutation, in the human UDP-galactose-4-epimerase gene, associated with generalized epimerase-deficiency galactosemia. Am J Hum Genet 64: 462–470.PubMedCrossRefGoogle Scholar
  36. Wong SS, Frey PA (1977) Fluorescence and nucleotide binding properties of Escherichia coli uridine diphosphate galactose 4-epimerase: support for a model for nonstereospecific action. Biochemistry 16: 298–305.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • J. S. Chhay
    • 1
  • C. A. Vargas
    • 1
  • T. J. McCorvie
    • 2
  • J. L. Fridovich-Keil
    • 1
  • D. J. Timson
    • 2
  1. 1.Department of Human Genetics, Emory University School of MedicineEmory UniversityAtlantaUSA
  2. 2.School of Biological SciencesQueen’s University Belfast, Medical Biology CentreBelfastUK

Personalised recommendations